Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Développement de nouveaux catalyseurs hétérogènes sélectifs pour l'amination directe des alcools

Autor: Ibáñez Abad, Javier

Les amines sont des composés largement utilisés dans l’industrie et dont, au vu des études récentes, la demande devrait augmenter dans les années à venir. À cet égard, le développement de technologies efficaces et écologiquement responsab

Externí odkaz: http://www.theses.fr/2017LIL10119/document

Identification of a Proteomic Signature for Predicting Immunotherapy Response in Patients With Metastatic Non-Small Cell Lung Cancer.

Autor: Mondelo-Macía P; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain; Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain., García-González J; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain., León-Mateos L; Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain., Abalo A; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Bravo S; Proteomic Unit, Instituto de Investigaciones Sanitarias-IDIS, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain., Chantada Vazquez MDP; Proteomic Unit, Instituto de Investigaciones Sanitarias-IDIS, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain., Muinelo-Romay L; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain; Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain., López-López R; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain; Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Díaz-Peña R; Fundación Pública Galega de Medicina Xenómica, SERGAS; Grupo de Medicina Xenomica-USC, Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain; Faculty of Health Sciences, Universidad Autónoma de Chile, Talca, Chile., Dávila-Ibáñez AB; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Electronic address: ana.belen.davila.ibanez@sergas.es.

Publikováno v: Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2024 Oct; Vol. 23 (10), pp. 100834. Date of Electronic Publication: 2024 Aug 29.

Clinical importance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in dogs with leishmaniasis.

Autor: Durán-Galea A; Hospital clínico Veterinario, Universidad de Extremadura, Avenida de la universidad s/n, Cáceres 10003, Spain., Cristóbal-Verdejo JI; Hospital clínico Veterinario, Universidad de Extremadura, Avenida de la universidad s/n, Cáceres 10003, Spain. Electronic address: jcristob@alumnos.unex.es., Barrera-Chacón R; Departamento de Medicina Animal, Universidad de Extremadura, Avenida de la Universidad s/n, Cáceres 10003, Spain., Macías-García B; Departamento de Medicina Animal, Universidad de Extremadura, Avenida de la Universidad s/n, Cáceres 10003, Spain., González-Solís MA; Departamento de Medicina Animal, Universidad de Extremadura, Avenida de la Universidad s/n, Cáceres 10003, Spain., Nicolás-Barceló P; Hospital clínico Veterinario, Universidad de Extremadura, Avenida de la universidad s/n, Cáceres 10003, Spain., García-Ibáñez AB; Hospital clínico Veterinario, Universidad de Extremadura, Avenida de la universidad s/n, Cáceres 10003, Spain., Ruíz-Tapia P; Departamento de Medicina Animal, Universidad de Extremadura, Avenida de la Universidad s/n, Cáceres 10003, Spain., Duque-Carrasco FJ; Departamento de Medicina Animal, Universidad de Extremadura, Avenida de la Universidad s/n, Cáceres 10003, Spain.

Publikováno v: Comparative immunology, microbiology and infectious diseases [Comp Immunol Microbiol Infect Dis] 2024 Apr; Vol. 107, pp. 102148. Date of Electronic Publication: 2024 Feb 23.

Red Blood Cells Protein Profile Is Modified in Breast Cancer Patients.

Autor: Pereira-Veiga T; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Bravo S; Proteomic Unit, Instituto de Investigaciones Sanitarias-IDIS, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain., Gómez-Tato A; CITMAga, University of Santiago de Compostela (Campus Vida), Santiago de Compostela, Spain., Yáñez-Gómez C; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Abuín C; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Varela V; Department of Oncology, University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain., Cueva J; Department of Oncology, University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain., Palacios P; Department of Oncology, University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain., Dávila-Ibáñez AB; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain., Piñeiro R; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain., Vilar A; Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain., Chantada-Vázquez MDP; Proteomic Unit, Instituto de Investigaciones Sanitarias-IDIS, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain., López-López R; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Department of Oncology, University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain. Electronic address: Rafael.lopez.lopez@sergas.es., Costa C; Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; CIBERONC, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain. Electronic address: clotilde.costa.nogueira@sergas.es.

Publikováno v: Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2022 Dec; Vol. 21 (12), pp. 100435. Date of Electronic Publication: 2022 Oct 28.